Ciphero | $2,500,000 | (Dec 23, 2025)
beycome | $2,500,000 | (Dec 23, 2025)
Givefront | $2,000,000 | (Dec 23, 2025)
Certified by Founder
Lodge
Qlaris Bio, Inc.
start up
United States
- Wellesley, Massachusetts
- 30/04/2024
- Series B
- $24,000,000
At Qlaris, our lead program is QLS-111, a novel topical ocular therapy that lowers intraocular pressure with a unique mechanism of action. QLS-111 is distinct from currently available therapies by selectively targeting episcleral venous pressure (EVP) and improving outflow distal to the trabecular meshwork. This novel mechanism may enable the improved treatment of diseases where EVP has limited therapy or has itself been pathologic, such as Normal Tension Glaucoma, Primary Open Angle Glaucoma, glaucoma associated with Sturge-Weber Syndrome, and also in combination with Minimally-Invasive Glaucoma Surgery (MIGS) devices.
- Industry Biotechnology
- Website https://qlaris.bio/
- LinkedIn https://www.linkedin.com/company/qlaris-bio-inc/
StretchSense | $2,300,000 | (Dec 23, 2025)
ZeroPhase | $6,800,000 | (Dec 23, 2025)
Peripheral Labs | $3,600,000 | (Dec 23, 2025)
Ethereal Exploration Guild | $21,000,000 | (Dec 23, 2025)
LatentForce | $1,700,000 | (Dec 23, 2025)
arcads AI | $16,000,000 | (Dec 19, 2025)
Amphix Bio | $12,500,000 | (Dec 19, 2025)
Edison Scientific | $70,000,000 | (Dec 19, 2025)
Thread | $18,000,000 | (Dec 19, 2025)